Your search found 154 Results

  1. 1
    Peer Reviewed

    High-risk human papillomavirus infection in the prediction of poor treatment response and disease recurrence in patients with vulvovaginal condyloma.

    Koo YJ; Kim YS; Min KJ; Hong JH; Lee JK

    International Journal of Gynaecology and Obstetrics. 2016 Jan; 132(1):20-4.

    Add to my documents.
  2. 2

    Important considerations in adolescent health maintenance: long-acting reversible contraception, human papillomavirus vaccination, and heavy menstrual bleeding.

    Brodie N; Silberholz EA; Spector ND; Pattishall AE

    Current Opinion In Pediatrics. 2016 Sep 26;

    Add to my documents.
  3. 3
    Peer Reviewed

    Factors related to non-compliance to HPV vaccination in Roraima-Brazil: a region with a high incidence of cervical cancer.

    Farias CC; Jesus DV; Moraes HS; Buttenbender IF; Martins IS

    BMC Health Services Research. 2016 Aug 22; 16(417):1-9.

    Add to my documents.
  4. 4

    Preclinical assessments of vaginal microbicide candidate safety and efficacy.

    Fernandez-Romero JA; Teleshova N; Zydowsky TM; Robbiani M

    Advanced Drug Delivery Reviews. 2015 Sep 15; 92:27-38.

    Add to my documents.
  5. 5
    Peer Reviewed

    Treatment and Follow-up of Human Papillomavirus Infected Women in a Municipality in Southern Brazil.

    Ruggeri JB; Dell Agnolo CM; Gravena AA; de Oliveira Demitto M; Lopes TC; Delatorre S; de Barros Carvalho MD; Consolaro ME; Pelloso SM

    Asian Pacific Journal of Cancer Prevention. 2015; 16(15):6521-6.

    Add to my documents.
  6. 6
    Peer Reviewed

    Cervical cancer: a comprehensive approach towards extermination.

    Bava SV; Thulasidasan AK; Sreekanth CN; Anto RJ

    Annals of Medicine. 2016 May; 48(3):149-161.

    Add to my documents.
  7. 7
    Peer Reviewed

    Cervical cancer in Botswana: Current state and future steps for screening and treatment programs.

    Grover S; Raesima M; Bvochora-Nsingo M; Chiyapo SP; Balang D; Tapela N; Balogun O; Kayembe MK; Russell AH; Monare B; Tanyala S; Bhat J; Thipe K; Nchunga M; Mayisela S; Kizito B; Ho-Foster A; Gaolebale BE; Gaolebale PA; Efstathiou JA; Dryden-Peterson S; Zetola N; Hahn SM; Robertson ES; Lin LL; Morroni C; Ramogola-Masire D

    Frontiers in Oncology. 2015 Nov; 5:Article 239.

    Add to my documents.
  8. 8

    Statement on safety of HPV vaccines.

    World Health Organization [WHO]. Global Advisory Committee on Vaccine Safety

    [Geneva, Switzerland], WHO, 2015 Dec 17. [3] p.

    Add to my documents.
  9. 9

    Investing in Cervical Cancer Prevention 2015-2020. Meeting report, London, November 3 & 4, 2015.

    Cody A; Goltz S; Wittet S

    [London, United Kingdom], Cervical Cancer Action, 2015. [13] p.

    Add to my documents.
  10. 10
    Peer Reviewed

    Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia.

    Aljunid S; Maimaiti N; Nur AM; Noor MR; Wan Puteh SEW

    BMC Public Health. 2016 Jan 23; 16(71):1-5.

    Add to my documents.
  11. 11
    Peer Reviewed

    Results of a health education message intervention on HPV knowledge and receipt of follow–up care among Latinas infected with high–risk human papillomavirus.

    Sanderson M; Khabele D; Brown CL; Harbi K; Alexander LR; Coker AL; Fernandez ME; Brandt HM; Fadden MK; Hull PC

    Journal of Health Care for the Poor and Underserved. 2015 Nov; 26(4):1440-1455.

    Add to my documents.
  12. 12

    Prevalence and clinical manifestations of male patients with anogenital warts attending a sexually transmitted disease clinic prior HPV vaccine recommentation.

    Jiamton S; Leeyaphan C; Maneeprasopchoke P; Omcharoen V

    Southeast Asian Journal of Tropical Medicine and Public Health. 2014 Nov; 45(6):1337-43.

    Add to my documents.
  13. 13
    Peer Reviewed

    Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy.

    Nakalembe M; Mirembe FM; Banura C

    Infectious Agents and Cancer. 2015; 10:17.

    Add to my documents.
  14. 14
    Peer Reviewed

    Control of cancer of the cervix in low- and middle-income countries.

    Denny L

    Annals of Surgical Oncology. 2015 Mar; 22(3):728-33.

    Add to my documents.
  15. 15
    Peer Reviewed

    Preventing and Controlling Cervical Cancer in Africa: A Call for Action.

    Okonofua F

    African Journal of Reproductive Health. 2015 Mar; 19(1):9-13.

    Add to my documents.
  16. 16
    Peer Reviewed

    30 years of preventive studies of uterine cervical cancer 1982-2012.

    Garrido JL

    European Journal of Gynaecological Oncology. 2015; 36(3):252-4.

    Add to my documents.
  17. 17

    Preventing cervical cancer through better guidelines in Guatemala.


    Washington, D.C., PATH, 2015 Jun. [4] p. (Advocacy Impact Case Studies)

    Add to my documents.
  18. 18
    Peer Reviewed

    Human papillomavirus vaccine acceptance among young men in Bangalore, India.

    Belani HK; Sekar P; Guhaniyogi R; Abraham A; Bohjanen PR; Bohjanen K

    International Journal of Dermatology. 2014 Nov; 53(11):e486-91.

    Add to my documents.
  19. 19
    Peer Reviewed

    Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya.

    Vermandere H; Naanyu V; Mabeya H; Vanden Broeck D; Michielsen K; Degomme O

    PloS One. 2014; 9(10):e109353.

    Add to my documents.
  20. 20
    Peer Reviewed

    [Efficacy of commercially available vaccines against HPV infection in women: a systematic review and meta-analysis] Eficacia das vacinas comercialmente disponiveis contra a infeccao pelo papilomavirus em mulheres: revisao sistematica e metanalise.

    Araujo SC; Caetano R; Braga JU; Costa e Silva FV

    Cadernos De Saude Publica. 2013 Nov; 29 Suppl 1:S32-44.

    Add to my documents.
  21. 21
    Peer Reviewed

    A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

    Joura EA; Giuliano AR; Iversen OE; Bouchard C; Mao C; Mehlsen J; Moreira ED Jr; Ngan Y; Petersen LK; Lazcano-Ponce E; Pitisuttithum P; Restrepo JA; Stuart G; Woelber L; Yang YC; Cuzick J; Garland SM; Huh W; Kjaer SK; Bautista OM; Chan IS; Chen J; Gesser R; Moeller E; Ritter M; Vuocolo S; Luxembourg A

    New England Journal of Medicine. 2015 Feb 19; 372(8):711-723.

    Add to my documents.
  22. 22
    Peer Reviewed

    The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador.

    Campos NG; Maza M; Alfaro K; Gage JC; Castle PE; Felix JC; Cremer ML; Kim JJ

    International Journal of Cancer. 2015; ([10] p)

    Add to my documents.
  23. 23

    Comprehensive cervical cancer control: A guide to essential practice. 2nd ed.

    World Health Organization [WHO]

    Geneva, Switzerland, WHO, 2014. [378] p.

    Add to my documents.
  24. 24

    Multipurpose prevention technologies: the future of HIV and STI protection.

    Fernandez-Romero JA; Deal C; Herold BC; Schiller J; Patton D; Zydowsky T; Romano J; Petro CD; Narasimhan M

    Trends in Microbiology. 2015; [8] p.

    Add to my documents.
  25. 25

    Strategic framework for the comprehensive control of cancer cervix in South-East Asia Region.

    Domercant JW; Guillaume FD; Marston BJ; Lowrance DW; World Health Organization [WHO]. Regional Office for South-East Asia

    MMWR. Morbidity and Mortality Weekly Report. 2015 Feb 20; New Delhi, India, WHO, Regional Office for South-East Asia, 2015. 64(6):137-140. [78] p.

    Add to my documents.